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Abstract
Background: International normalized ratio (INR) self-testing can improve the management of anticoagulation
therapy with warfarin for the patients following mechanical heart valve replacement. Several reviews and studies
have demonstrated self-management as an option to improve patient’s outcome considerably after mechanical
heart valve replacement. We sought to analyze the security, economy and discuss the prospect of self-testing of
anticoagulation therapy in patients following mechanical heart valve replacement in China, and evaluate the
accuracy and stability of CoaguChek XS portable INR-testing device.
Methods: This was a prospective self-controlled clinical study conducted with 526 patients receiving oral warfarin
anticoagulation therapy after mechanical heart valve replacement in the period of Mar.1, 2012 – Nov.1, 2012 in
Cardiovascular Surgery Department of West China Hospital of Sichuan University. The same patient performed INR
testing with CoaguChek XS portable coagulometer (group1) and central lab (group 2) in parallel. The follow-up time
was 6 months. Meanwhile, a questionnaire was handed out to survey the expenses required for the re-examination
visits to the hospital, time, and anticoagulation complications.
Results: No severe anticoagulation complications occurred in all the patients. No significant difference of the INR
results were observed between group 1 and group 2, they showed significant relevance, r = 0.953(p < 0.05).
Compared with the conventional method of INR testing in hospital, the portable coagulometer is convenient,
quick and less traumatic. Self-testing of anticoagulation therapy reduced the cost and the time required for
re-examination.
Conclusions: Results of CoaguChek XS monitor are precise and have a good consistency and stability as compared
with traditional laboratory testing. For the patients receiving anticoagulation therapy after mechanical heart valve
replacement, the self-testing of anticoagulation therapy with portable coagulometer is a safe choice, and it has a
promising future application in China.
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Background
As one of the most common adult cardiac surgeries,
there has been over 200,000 cases of cardiac valve re-
placement surgeries in China [1]. The mean age of pa-
tients with valvular diseases in China are young and over
98% of them received cardiac mechanical valves [2].
After mechanical valve replacement surgery, the patient
must adhere to a life long anticoagulation therapy,and
the limited therapeutic index of warfarin requires regular
check of the INR to adjust its anti-coagulation intensity
to improve the quality of anticoagulation management
and avoid complications with either higher or lower
blood-coagulation level [3-5].
Traditional method to monitor anticoagulation requires
the patients to visit professional medical institutions regu-
larly. Plasma after anticoagulation centrifugation is drawn
from venous blood and sent to lab for testing . Doctor will
instruct them to adjust the dosage of orally administered
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warfarin. It has the advantage of accurate measurement
which gives the patient professional guidance on anticoa-
gulation after testing. However, such re-examination visits
are costly and time-consuming. Many of them failed to re-
ceive re-examination on a regular basis. It was shown in a
study, the incidence of follow-up re-examination of coagu-
lation functions received after more than half a year after
surgery account for 38% of the total [6]. Excessively low
frequency of monitoring may obviously affect the anticoa-
gulation therapy management, increasing the incidence of
complications, and therefore, greatly increase the risks of
anticoagulation therapy [7,8].
Self-testing of INR using Portable point-of-care (POC)
coagulometers has been used in clinical application for
nearly 20 years in other countries. The portable co-
agulometer features easy manipulation, fast and accurate
measurement. The patients needing oral warfarin antic-
oagulation in developed western countries have started
to use portable coagulometer for self-testing and self-
management [9-14]. In China, reports and applications
are limited to the analysis of lab data of portable coagu-
lometer [14,15]. There are no clinical application reports
or evaluation of economy based on massive samples, or
any reports on self-testing of anticoagulation therapy.
Presently in China, although most patients have ac-
cepted low-intensity anticoagulant therapy after cardiac
valve replacement, the incidence rates of relevant com-
plications still remains high, mainly due to the fact that
the patients conduct anticoagulation testing with a low
frequency and fail to regularly re-examine or timely ad-
just the dosage of warfarin which results in complica-
tions. Overseas literatures indicate that self-monitoring
may increase patient’s monitoring frequency and reduce
the incidence rate of complications [16,17]. Therefore, it
is compulsory to conduct clinical studies on self-testing
of anticoagulation therapy after mechanical heart valve
replacement surgery. The purpose of this study is to
analyze the security, economy and discuss the prospect
of self-testing of anticoagulation therapy in patients fol-
lowing mechanical heart valve replacement in China,
and evaluates the accuracy and stability of CoaguChek
XS portable INR-testing device.
Materials and methods
The design and implementation of this study has been
conducted based on the approval of West China Hospital
of Sichuan University Clinical Test Ethics Committee and
adhered to the tenets of the Declaration of Helsinki. Ad-
ditionally, the written informed consent was obtained
from the patients.
Patients
We selected the 526 consecutive patients conducting
anticoagulation therapy follow-up from Mar.1, 2012 –
Nov. 1, 2012, after receiving mechanical valve replace-
ment surgery in the Cardiovascular Surgery Department
of West China Hospital of Sichuan University. In this
study, we used the average exchange rate in 2012 of the
RMB (Chinese Yuan) against the U.S dollar for 6.3125.
The inclusion criteria of the patients were:
 Receiving only oral warfarin for anticoagulation
therapy after receiving mechanical valve
replacement surgery.
 Without history of administering other medicines
affecting anti-coagulation functions.
 Without severe coagulation diseases.
 Without drug and alcohol abuse.
 Having a good compliance.
 Patients or their actual caregivers having the ability
to fulfill self-testing criteria recommended by
professional bodies.
Methods
The follow-up time is 6 months. Low-intensity anticoagu-
lation therapy is accepted by the patients after mechanical
valve replacement. The INR target value of anticoagula-
tion therapy: AVR 1.5-1.8, MVR and DVR1.8-2.0, TVR in-
cluding other valve replacement 2.0-2.5. According to the
current tradition, the monitoring frequency is 1 week/time
within one month after the valve replacement surgery,
2 weeks/time within 1–3 months after the valve replace-
ment surgery, and 1–3 months/time after 3 months. All
these patients attend the hospital outpatient anticoagu-
lation clinic for INR testing. Professional physicians will
adjust the dosage of orally administered warfarin.
To re-examine coagulation functions of these patients,
the traditional central lab testing methods and self-testing
methods are used in parallel to check and record the
INR values of the patients. In the former case, peripheral
venous blood of about 3 cm3 is collected by the laboratory
staff, and added into a standard sodium citrate anticoagu-
lation blood collection tube, and tested with STAGO
STAR automatic coagulometer after plasma separation. In
the latter case, about 0.01 cm3 blood at the end of capil-
lary of finger is collected by the patients themselves or
their actual caregivers, and added into corresponding area
on the dry reaction test strip, and tested with CoaguChek
XS portable coagulometer.
For the purpose of analyzing the costs of the two
testing methods, the general conditions of the patients,
expenses (registration fee, testing fee, transportation fee
and accommodation, etc.) and time (transportation and
accommodation time + time of registration, testing, diag-
nosis, queuing and waiting, etc.) for the re-examination
visits to the hospital were investigated in the form of
questionnaire. Meanwhile, survey the anticoagulation
complications. In the study, the expenses and time for
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each re-examination visit varies with the geographic
location of the patients, so patients from different local-
ities were grouped into Chengdu Group (Local group),
Sichuan Group (except Chengdu) (Within-Sichuan Group),
and Other Locality Group (Outside-Sichuan Group).
In the analysis using SPSS 18.0 statistic software, the
test results were expressed in average ± standard devia-
tion (x  s), and p values less than 0.05 were considered
statistically significant. The linear regression and cor-
relation of the two methods were analyzed and scatter
diagram and regression line of the two were plotted;
meanwhile, Bland-Altman analysis was adopted to plot
scatter diagram with the deviation and average of INR
measured respectively with the two methods as subject
of study to obtain 1imits of agreement and compare the
correlation between the standard deviation of INR dif-
ference and the imprecision of INR values measured re-
spectively with the two instruments, and evaluate the
consistency of INR values. Perform comparison study on
the economic indicators such as expenses and time with
two anticoagulation monitoring methods for patients of
various localities.
Results
Basic characteristics of the study object
The cases including 177 cases of male patients (33.7%)
and 349 cases of female patients (66.3%), with age of
20–76 (48.75 ± 10.29). There are 263 cases of mitral
valve replacement (MVR) (50.0%), 91 cases (17.3%) of
aorta valve replacement (AVR), 147 cases (27.9%) of mi-
tral valve and aorta valve replacement (DVR), 12 cases
(2.3%) of tricuspid valve replacement surgery (TVR), 9
cases (1.7%) of mitral valve and tricuspid valve re-
placement surgery (MVR + TVR), 4 cases(0.8%) of mitral
valve and aorta valve with tricuspid valve replacement sur-
gery (DVR + TVR). All the patients use St. Jude Medical
bileaflet Mechanical Heart Valve. Patients from different
localities were grouped into three groups. Among them,
141 cases (26.8%) belong to Local Group; 368 cases
(70.0%) belong to Within-Sichuan Group; and 17 cases
(3.2%) belong to Outside-Sichuan Group (Table 1).
Complications and patients satisfaction
According to the questionnaire, general complications
such as gum bleeding, nasal cavity bleeding, profuse men-
struation visible hematuria were observed in 19 patients,
and no intracranial hemorrhage and other severe compli-
cations were observed. During this study, thrombus for-
mation in the heart was judged through echocardiogram.
We found no embolism or thrombus formation in this
group of patients (Table 2).
Traditional lab testing requires drawing 3 cm3 of venous
blood while portable coagulometer only needs to draw
about 0.01 cm3 of blood from the end of fingertip capillary,
which may alleviate trauma and pain to the patient, and is
thus more favorable to patients as compared with trad-
itional blood collection. In the study, 409 persons (77.8%)
preferred fingertip blood collection, 47 persons (8.9%) pre-
ferred vein blood collection and 70 persons (13.3%) con-
sidered both acceptable. In the study, we also found that
the patients with anticoagulation therapy in China knew
little about portable coagulometer and were worried about
this “new type” of monitoring instrument. 485 persons
(92.2%) have never heard of portable coagulometer; 432
persons (82.2%) were worried that the measured value of
the instrument itself or the measured value obtained by
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them may not be accurate; 146 persons (27.8%) thought
that the instrument was too expensive; 333 persons
(63.3%) worried about the adjustment of treatment regi-
men after self-monitoring.
Comparison of INR measurement values using the two
testing methods
Five hundred and twenty six patients were tested for 2079
times in total with CoaguChek XS portable coagulometer
and traditional central lab automatic coagulometer in par-
allel. The results of linear regression analysis on the two
groups of data are shown as the Figure 1. It is shown that
the regression equation for measured value of CoaguChek
XS portable coagulometer (y axis) and lab measured value
(x axis) is y = 0.155 + 0.911x. Good correlation between
the INR measured values of the two groups can be ob-
served (r = 0.953, p < 0.05). Meanwhile, its bias can be ob-
served with Bland-Altman diagram, as shown in Figure 2,
the gap between the measured value from CoaguChek XS
portable coagulometer and the measured value from
traditional central lab is −0.033 ± 0.15732, proving good
consistency between the two groups.
Comparison of anticoagulation testing costs
The total expenses of the three groups of outpatient pa-
tients were counted (Table 3), in which, the expenses
incurred to patients of Chengdu urban areas mainly
came from registration fee and testing fee of the hospital
with the average expenses of 9.83 ± 1.61 U.S dollar. The
patients in other regions of Sichuan may afford more
transportation fee and accommodation of 1–2 days, who
were the majority of patients receiving anticoagulation
outpatient diagnosis, accounting for 70%, with average
expenses of 63.00 ± 45.53 U.S dollar. The number of
patients from other provinces was small. They had to
pay more for transportation and accommodation for re-
examination visit to the outpatient with average expenses
of 150.50 ± 69.60 U.S dollar. From the study, it can be seen
that patients from various regions afforded different ex-
penses for re-examination mainly due to the difference of
transportation fee and accommodation fee varying with
the distance while the expenses of diagnosis were basically
the same. Pairwise comparisons among the three groups
showed P < 0.05, all statistically significant. CoaguChek XS
(Roche) portable coagulometer’s test strip is currently sold
9.5-14.3 dollar/strip. In China, Guangdong province and
Jiangsu province have included the test strips into the
scope of Medicare. By the comparison of the expenses re-
quired for each monitoring, we may see that the expenses
for traditional monitoring methods of the Local Group of
patients were slightly lower than those of the portable coa-
gulometer monitoring, p > 0.05, the difference showed no
statistically significant, while the expenses for traditio-
nal monitoring methods of the Sichuan Group (except
Chengdu) and Outside-Sichuan Group of patients were
obviously higher than those of the portable coagul-
ometer monitoring, p < 0.05, the difference are statisti-
cally significant.
Figure 1 INR linearity regression diagram of lab testing and CoaguChek XS testing.
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Patients from various regions consume almost the
same amount of time in the hospital on the day of visit,
mainly including: registration, queuing up for blood col-
lection, waiting for reports, waiting for diagnosis, being
diagnosed by doctors, paying fees, etc., about 3–5 hours
in total. The difference in time mainly lies in the dif-
ference of time consumed in accommodation and in
the journey (Table 4). For patients in urban areas of
Chengdu, the time spent in the hospital accounts for a
large proportion in the total time consumed. For pa-
tients outside Chengdu, the time consumed for accom-
modation and journey does so. Merely comparing the
time required from blood collection to getting the result,
lab monitoring usually takes 2–3 hours, about 4 hours
to the maximum (155.17 ± 38.25 minutes), while in case
of portable coagulometer monitoring, it only takes about
1 minute to complete the process from blood collec-
tion to getting results, and if adding the time for pre-
warming of instrument, sterilization, fingertip punctur-
ing, the total time is about 0.04 ± 0.03 hours. Conduct
paired T-test for the two groups of data, p < 0.01, it is
concluded that the time required for group one is ob-
viously less than group two.
The annual average income per capita of Sichuan
Province in 2012 was 6,007.76 dollars, namely monthly
average income of 500.59 dollars or daily salary of 16.63
dollars. To set a uniformed standard, the economic
benefits of Outside-Sichuan Group were evaluated using
Figure 2 Diagram of bias of the INR values from lab testing and from CoaguChek XS testing.
Table 3 Comparison of re-examination expenses of the patients from different areas
Local group Within Sichuan group Outside Sichuan group
Number of patients (Persons) 141 (26.8%) 368 (70.0%) 17 (3.2%)
Testing fee (dollar) 1.74 1.74 1.74
Registration fee (dollar) 3.17 3.17 3.17
Transportation fee (dollar) 0-4.75 (1.97 ± 0.84) 15.84-126.73 (45.36 ± 21.46) 63.37-158.42 (100.63 ± 38.49)
Accommodation fee (dollar) 0 0-31.67 (14.97 ± 9.25) 15.84-63.37 (24.85 ± 13.64)
Others (dollar) 0-3.17 (1.72 ± 0.98) 0-9.50 (4.06 ± 2.74) 0-12.67 (5.68 ± 3.07)
Total (dollar) 4.91-12.67 (9.83 ± 1.62) 31.68-154.42 (63.00 ± 45.53) 95.05-221.78 (150.50 ± 68.60)
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the average income of Sichuan. Considering the socially
necessary labor time consumed, if the patient performs
self-monitoring of anticoagulant therapy, it may save the
time consumed in visits to the hospitals, of which the eco-
nomic benefits are evaluated (Table 5). Time-saving effect
of the Within-Sichuan Group and Outside-Sichuan Group
was more substantial. Some patients need companion, so
that such effect may be doubled.
Discussion
During this study, general complications such as gum
bleeding, nasal cavity bleeding, profuse menstruation
visible hematuria were observed in 19 patients, and no
intracranial hemorrhage and other severe complications
were observed. In this experiment, we may see that the
measured values of portable coagulometer were well
consistent with those of the traditional lab methods. In
our study, it can be easily seen that Within-Sichuan pa-
tients took a large percent in the out-patient patients,
other expenses incurred to these patients for out-patient
re-examination were much higher than the expenses
required for blood collection testing, and the total ex-
penses for each out-patient visit was also higher than that
of portable coagulometer self-monitoring. Meanwhile, tes-
ting with portable coagulometer can obviously save the
time consumed in each re-examination visit of each antic-
oagulation patient.
Traditional lab monitoring of INR is usually used to
test the accuracy of the measured value of other INR
testing equipment as a gold standard [18]. In our study,
results of CoaguChek XS monitor were consistent with
relevant overseas and domestic reports [15,18-25]. There
were also other reports that when INR value was greater
than 3.5, the measured value of CoaguChek XS portable
coagulometer will be higher than the lab measured
value, showing decreased accuracy. In this experiment,
since all the patients adopted low-intensity anticoagulant
therapy, INR was maintained at a low level; therefore
few data have INR in the measured value greater than
3.5, thus disabling a systematic evaluation of the cor-
relation of the two [20]. However, when INR is main-
tained at a low level, the measured value of portable
coagulometer is convincing and thus suitable to the
monitoring and management of patients in China.
For the patient as an individual, the economic benefit
comparison varies greatly among different countries. Such
gap mainly comes from the difference of Medicare system
[26]. In some countries with consummated Medicare,
portable coagulometer and the test strips have been listed
as items of medical insurance, thus alleviating the burden
of the patients. In the case of China presently, patients in
most areas shall pay relevant expenses on their own. In a
long run, the life of portable coagulometer is 30,000 times
with zero maintenance cost and thus eliminating the need
of frequent replacement of instrument. Even if the initial
costs such as procurement of instrument are included,
the average direct cost of portable coagulometer self-
monitoring is obviously lower than that of the traditional
monitoring methods. Testing with portable coagul-
ometer can obviously save the time consumed in each
re-examination visit of each anticoagulation patient.
Meanwhile, it also reduced the workload of the out-
patient doctors. The time saved, as converted into eco-
nomic benefits may further prove the cost advantages of
patient self-monitoring.
Presently, in some developed western countries, most
patients have adopted portable coagulometer to perform
self-monitoring (PST: patients measure their INR values
by themselves, and professional doctors or pharmacists
gave the adjusted regimen for warfarin administration)
and self-management (PSM: patients measure their INR
values by themselves, and adjusted their warfarin admi-
nistration regimen by themselves) of oral anticoagulant
treatment, and also accumulated lots of experience
[13,27,28]. In China, the portable coagulometer is rather
less popular. The main reasons include:
 Patients are concerned about short-term cost while
ignoring long-term cost. One unit of CoaguChek XS
portable coagulometer costs 1267. 33 dollars, which
is a large expense for many Chinese families. The
initial cost is obviously higher than that of the
traditional monitoring method.
 Not well-informed of the self-monitoring of
anticoagulant therapy. From the questionnaire, it
was shown that patients receiving anticoagulation
treatment in China knew too little about portable
coagulometer and most patients have never heard of
portable coagulometer, and therefore balked at using
self-monitoring and management.
Table 4 Comparison of time consumed for re-examination
between patients adopting different monitoring methods
Region Time consumed (hours)
Local group 12.00-19.20 (12.48 ± 2.40)
Group 1 Within-Sichuan group 24.00-84.00 (47.76 ± 18.72)
Outside-Sichuan group 48.00-108 (64.08 ± 13.92)
Group 2 0.03-0.08 (0.04 ± 0.03)
Table 5 Cost-benefit analysis of each testing in patient





New sum of time
and cost benefits
Local group 8.65 −1.10 6.60
Within-Sichuan group 33.10 51.12 84.22
Outside-Sichuan group 44.41 138.61 183.03
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 In many remote areas, patients who only have low
level of education fail to complete self-monitoring of
anticoagulant therapy.
 In most areas in China, such item has not been
covered by Medicare, indirectly increases expenses
afforded by the patients.
With the economic development of China, especially
the increase of income of rural patients, the price of port-
able coagulometer is no longer prohibitive to the patients.
If the importance of anticoagulant therapy and the advan-
tages of self-monitoring of anticoagulant therapy are
further informed to the patients, portable coagulometer
may become the first choice for anticoagulation patients,
enjoying a prospect of wide application. Due to the unrea-
sonable distribution of medical resources in China, the
traditional monitoring methods brought about heavy eco-
nomic burden to patients in remote areas. To alleviate
such burden, these patients lengthen their re-examination
intervals on their own will, thus becoming less compliant,
and more vulnerable to complications. Therefore, such
kinds of patients are the most ideal group for conducting
self-monitoring of anticoagulant therapy with portable
coagulometer.
Limitation
These findings are subject to certain limitations. First,
we followed up the patients for a short time period, and
the study methods were found to be less than ideal. Se-
cond, we only describe the present situation of anticoa-
gulation monitoring in patients after mechanical heart
valve replacement in China and point to the failure of
regular monitoring in a high percentage of patients. The
final limitation of this study is that the economic eva-
luation is simple.
Conclusion
The measured value of CoaguChek XS INR monitor is
accurate, showing good consistency and stability with
the results of traditional lab testing, while saving cost
and time, improving monitoring frequency, reducing the
incidence of anticoagulation complications, improving
the life quality of patients and showing good prospect. It
is advisable to intensify the self-monitoring and manage-
ment of patient and improve the knowledge of patients
in this regard. Meanwhile state support such as inclusion
into medical insurance is also required for its further
popularization.
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